About Kymos Group

Kymos Group is a GLP/GMP-certified, GCP compliant, EMA, ANVISA, and FDA-inspected European contract research organization (CRO) offering an all-encompassing range of bioanalytical and quality control services for small molecules, biologics and advanced therapies.

about-us-our-vision

The core of our being

Our Vision & Mission

We are fully committed to having a social impact by promoting diversity, gender equality, employee well-being, environmental protection, and social responsibility.

Three sites in Europe – One strong group

Our Global Reach

Our headquarters and main laboratory are in Barcelona (Kymos Spain), and additional laboratories are located in Frankfurt (Kymos Germany, originally Prolytic) and Ancona (Kymos Italy, originally Pharmaprogress).

Kymos Group is committed to supporting pharma, biotech, generic, and biosimilar clients in over 60 countries worldwide, helping them develop their products, reducing costs, and improving time to market with our unique, customized approach and multidisciplinary understanding of the entire development and manufacturing process: from early R&D, product development, preclinical, and clinical phases to final approval and post-marketing requirements.

Kymos Spain

Kymos S.L. was founded in Barcelona in 2001 by a team of R&D scientists with decades of experience in pharmaceutical development from early research to final formulation and scale up trials for commercialization.

  • Bioanalysis of Small Molecules (aka Mass Spec and Permeation)
  • Bioanalysis of Large Molecules (aka Immunology)
  • Analytical Development and Validation
  • Quality Control of Small Molecules
  • Quality Control of Large Molecules (aka Biopharmaceutical testing)
  • Elemental Analysis
  • Microbiology
  • Stabilities
Kymos Germany

Prolytic GmbH was founded in 2002 by a veteran group of scientists from Viatris GmbH, the largest business unit of Degussa/ASTA Medica AG. The newly formed CRO, based in Frankfurt, focused on the delivery of bioanalytical and pharmacokinetics services to clients in the pharmaceutical sector. In 2020 Prolytic became part of the Kymos group.

  • Bioanalysis of Small Molecules (aka Chromatography)
  • Bioanalysis of Large Molecules (aka Biology)
  • Bioanalysis of Nucleic Acids
Kymos Italy

Pharmaprogress s.r.l. was legally founded in 1999 by former Angelini group executive and began operating as a CRO in 2001. A 700m2 fit-to-purpose laboratory was built in Camerata Picena, near Ancona, and was GMP approved by Italian Health Authorities. 

Later in 2023, the facilities were moved to Monsano where a new laboratory of 1800m2 was built and inaugurated the following year.

  • Stabilities, Analytical Development and Validation
  • Quality Control of Small Molecules (aka Quality & Mass Spectrometry)
Kymos Branch in South Korea

In 2024, Kymos Group established a Liaison Office in Seoul, South Korea, to enhance support for our international clients across the Asia-Pacific (APAC) region.

Located in the prestigious ASEM Tower, this office serves as our primary contact point for pharmaceutical and biotechnology companies operating in the region.

ABOUT US

Our Commitment & Success

Rather than just a service provider, Kymos aims to be a reliable partner: Fully committed to our clients’ goals and the projects we are entrusted with; delivering high-quality services, reliable in terms of pricing in order to sustain our client’s competitiveness; upholding deadlines because the time to market is a key element to success; and constantly dedicated to research and development as the only way to meet the new challenges of a rapidly-changing business environment.

30% Sales growth

We are constantly growing at 2-digit percentages thanks to the implementation of new services and capabilities.

85% Returning clients

We are proud to have a very high percentage of returning clients on a yearly basis.

50% Quotations accepted

We have a high ratio of quotations approved, reflecting a consistent offer in terms of quality and fair prices.

30% New clients

The percentage of new clients is increasing year after year, mainly due to our efforts in internationalization.

From Vision to growth

Our History

Kymos S.L. was founded in 2001 by a team of R&D scientists with decades of experience in pharmaceutical development from early research to final formulation and scale up trials for commercialization. The company was established at the Barcelona Science Park and rapidly expanded despite high competition. In 2011 Kymos took over Ipsen Pharma’s immunology team to create a pioneering biological division. In 2015 Kymos moved to a brand-new laboratory at the Vallès Technology Park. In 2016 Kymos acquired Italian CRO Pharmaprogress. In 2018, steady growth called for two successive extensions with a new office building and laboratories. In 2020 Kymos acquired German CRO Proytic. In 2021 the Kymos Group is made up of a two-building HQ plus two European sites, 14 laboratory departments, 170 highly trained experts, and 5,000 m2 worth of facilities and top-of-the-line instruments. In 2023-2024 our Italian site was expanded with a new building, and a lab extension has started in Spain.

Yong Suk Yang

Global QC Operation Team Manager

celltrion-logo
quotation-mark

We are currently developing multiple new biosimilar projects and consider Kymos one of the best CROs in Europe for drug release and testing

Dr. Dino Mangion

Head of Malta Operations

Combino Logo
quotation-mark

We were positively impressed when Kymos reacted to our needs by investing in their stability capabilities, and now, two years down the line, with projects in full-swing, I can safely say that we made the right choice. In Kymos we have found a reliable, committed, trustworthy and professional partner.

Dr. Marius Strunk

Senior Pharmaceutical Development Manager

Helm Logo
quotation-mark

Back in 2017 there weren’t many analytical CROs able to carry out Franz cell assays and Kymos’ pioneering work was pivotal for the registration of our product.

Dr. Pablo Avilés

PharmaMar Logo
quotation-mark

Kymos offered superior historical expertise by being exposed to so many different clients, pharmacological compounds, and therapeutic areas. They addressed and anticipated very diverse problems.

Jaime Algorta

Medical Affairs Director

quotation-mark

I have had a long and fruitful experience with Kymos and have a huge interest in their participation owing to their reliability.

OMEICOS THERAPEUTICS

Omeicos_Logo
quotation-mark

Prolytic is our analytical partner throughout the entire drug development process. Such a long and complex process requires a laboratory you can trust. Professional yet flexible, Prolytic accompanies us through the preclinical and clinical phases.

Dr. Meike Saul

Research Group Leader

quotation-mark

Establishing robust miRNA methods for valuable results is tricky. The team at Prolytic have been a key collaboration partner. With their 30 years of experience in bioanalytics and broad know-how in different techniques, study types, and substance groups, we were able to quickly develop a reproducible and reliable analysis method for miRNAs

Posa’t en contacte amb nosaltres

Troba una ubicación a prop teu